Interferon beta-1b inhibits reactive oxygen species production in peripheral blood monocytes of patients with relapsing-remitting multiple sclerosis

被引:18
|
作者
Lucas, M
Sánchez-Soliño, O
Solano, F
Izquierdo, G
机构
[1] Virgen Macarena Univ Hosp, Mol Biol Serv, Seville, Spain
[2] Schering Espana SA, Madrid, Spain
[3] Virgen Macarena Univ Hosp, Neurol Serv, Seville, Spain
关键词
D O I
10.1016/S0197-0186(98)00014-X
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
We studied the rate of reactive oxygen species (ROS) production by monocytes 'ex vivo' in a cohort of healthy individuals, in a group of MS patients undergoing treatment with interferon beta-lb and another group of MS patients who refused treatment with interferon beta-1b. The rate of ROS production in healthy individuals was slightly lower than in non-treated MS patients. The lower rate of ROS production was obtained in monocytes of MS patients treated with interferon beta-1b. These results indicate that the treatment of relapsing-remitting MS patients with interferon beta-lb rendered the NADPH oxidase of the monocytes less sensitive to trigger reactive oxygen species (ROS). (C) 1998 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:101 / 102
页数:2
相关论文
共 50 条
  • [41] Interferon beta-1a in relapsing-remitting multiple sclerosis: A meta-analysis
    Blumhardt, LD
    NEUROLOGY, 1999, 52 (06) : A498 - A498
  • [42] Rationale for early treatment with interferon beta-1a in relapsing-remitting multiple sclerosis
    Munschauer, FE
    Stuart, WH
    CLINICAL THERAPEUTICS, 1997, 19 (05) : 868 - 882
  • [43] Side effects of interferon-beta 1a in relapsing-remitting multiple sclerosis
    Lotfi, J
    Adibnejad, S
    Beheshtian, A
    JOURNAL OF NEUROLOGY, 2004, 251 : 64 - 64
  • [44] Effects of statins on intramuscular interferon beta-1a for relapsing-remitting multiple sclerosis
    Rudick, R.
    Pace, A.
    Panzara, M.
    Rani, S.
    Schrock, J.
    Calabresi, F.
    Confavreux, C.
    Galetta, S.
    Lublin, F.
    Radue, E. W.
    Stuart, W.
    Weinstock-Guttman, B.
    Wynn, D.
    MULTIPLE SCLEROSIS, 2007, 13 : S57 - S57
  • [45] RANTES production and expression is reduced in relapsing-remitting multiple sclerosis patients treated with interferon-β-1b
    Iarlori, C
    Reale, M
    Lugaresi, A
    De Luca, G
    Bonanni, L
    Di Iorio, A
    Feliciani, C
    Conti, P
    Gambi, D
    JOURNAL OF NEUROIMMUNOLOGY, 2000, 107 (01) : 100 - 107
  • [46] Injectable interferon beta-1b for the treatment of relapsing forms of multiple sclerosis
    Jankovic, Slobodan M.
    JOURNAL OF INFLAMMATION RESEARCH, 2010, 3 : 25 - 31
  • [47] Review of interferon beta-1b in the treatment of early and relapsing multiple sclerosis
    Paolicelli, Damiano
    Direnzo, Vita
    Trojano, Maria
    BIOLOGICS-TARGETS & THERAPY, 2009, 3 : 369 - 376
  • [48] Interferon β-1b modulates MCP-1 expression and production in relapsing-remitting multiple sclerosis
    Iarlori, C
    Reale, M
    De Luca, G
    Di Iorio, A
    Feliciani, C
    Tulli, A
    Conti, P
    Gambi, D
    Lugaresi, A
    JOURNAL OF NEUROIMMUNOLOGY, 2002, 123 (1-2) : 170 - 179
  • [49] Human herpesvirus 6 is latent in peripheral blood of patients with relapsing-remitting multiple sclerosis
    Rotola, A
    Cassai, E
    Tola, MR
    Granieri, E
    Di Luca, D
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1999, 67 (04): : 529 - 531
  • [50] High-dose interferon beta-1b (IFNB) improves clinical response in more severely disabled relapsing-remitting (RR) multiple sclerosis (MS) patients
    Durelli, L
    Oggero, A
    Verdun, E
    Isoardo, GL
    Barbero, P
    Bergamasco, B
    NEUROLOGY, 2000, 54 (07) : A62 - A62